-
Z17 and Astrocyte Amyloid Clearance in Alzheimer’s
2026-10-10
The 2026 International Journal of Biological Macromolecules study reports Z17 as a direct CHI3L1 inhibitor that counteracts inflammatory signaling and restores several astrocyte functions relevant to amyloid handling. Its evidence is compelling at the cellular, mechanistic level, but remains preclinical: the work does not establish plaque clearance, therapeutic efficacy, or safety in animal models or patients.
-
Erastin and Ferroptosis: Evidence, Context, Limits
2026-10-10
Erastin is a widely used ferroptosis inducer for studying cystine metabolism, redox control, iron dependence, and genotype-linked tumor vulnerabilities. This overview compares foundational Erastin research with a 2026 study of realgar transforming solution in NB4 leukemia cells, emphasizing evidence strength, provenance, and limits of interpretation.
-
Bromodomain Inhibitor (+)-JQ1: Evidence Overview
2026-10-09
A source-grounded overview of (+)-JQ1 examines BET biology, BRD4–RAC1 signaling in breast cancer, reported apoptosis and inflammatory findings, conceptual applications, and the limits of preclinical evidence.
-
Dihydroartemisinin: Evidence, Uses and Limitations
2026-10-09
Dihydroartemisinin is a defined artemisinin derivative with established relevance to malaria research, but the supplied evidence does not directly support every claimed application. This overview separates catalog information from primary research, compares DHA claims with a recent cabamiquine pharmacodynamic study, and outlines evidence strength, translational boundaries, and unanswered questions.
-
Parthenolide, NLRP3, and Gout-Like Inflammation
2026-10-08
A 2026 study reports that parthenolide reduced MSU-associated inflammation, influenced NLRP3 inflammasome activation, and improved biochemical features of experimental hyperuricemia. Its main contribution is a cross-model view connecting inflammatory signaling, phagocytic behavior, uric acid metabolism, and renal injury, although the findings remain preclinical.
-
Phosbind Acrylamide: Reading Causal Evidence
2026-10-08
Phosbind Acrylamide enables antibody-independent protein phosphorylation analysis through phosphate-dependent mobility shifts. This article shows how that readout can strengthen, but not independently prove, mechanistic models linking ubiquitination, autophagy, and fungal pathogenicity.
-
Gastric Cancer Assembloids: What the Study Shows
2026-10-07
Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations. Their findings show that stromal context can reshape gene expression and drug sensitivity, supporting more physiologically relevant preclinical oncology research while also defining important limits for translation.
-
Indole-3-pyruvic Acid: Evidence and Research Context
2026-10-07
Indole-3-pyruvic acid (IPA) is a tryptophan metabolite with distinct roles in auxin biology and AhR-linked immune research. Current evidence supports IPA as a mechanistic research compound, while animal findings and vendor-reported cancer effects remain insufficient for clinical extrapolation.
-
Cl-Amidine Trifluoroacetate Salt: Reading PAD4 Evidence
2026-10-06
Cl-Amidine trifluoroacetate salt is a PAD4-focused research tool with relevance to cancer research, rheumatoid arthritis research, and inflammatory disease models. This evidence-centered guide separates direct enzyme inhibition from downstream phenotypes and explains why the Dinaciclib–VHL study should inform interpretation without being treated as evidence for Cl-Amidine.
-
Isradipine (Dynacirc) in Calcium Channel Research
2026-10-06
Isradipine (Dynacirc) is best understood as a pharmacological probe of L-type calcium-channel signaling, with established relevance to vascular physiology and a plausible but incompletely demonstrated role in neuronal calcium research. The supplied evidence on v-Agatoxin-IVA highlights why channel-subtype assignments require careful interpretation and should not be treated as direct evidence for isradipine’s neuroprotective efficacy.
-
Wnt/NR2F2 Drives Platinum Resistance in Brain Metastasis
2026-10-05
Liu and colleagues linked acquired platinum resistance in lung cancer-derived brain metastasis to high glutathione consumption, GPX4/GSTM1 activity, and suppression of ferroptosis. Their integrated preclinical evidence further identified Wnt/NR2F2 signaling as a transcriptional mechanism associated with GPX4 upregulation, while also indicating that GPX4 inhibition can improve platinum sensitivity in experimental models.
-
Ivermectin and GSDMC in Pancreatic Cancer: Five Questions
2026-10-04
A source-grounded overview separates Ivermectin’s established anti-parasitic context from a preclinical study of GSDMC in pancreatic ductal adenocarcinoma, examining principles, evidence quality, interpretation, scope and limitations.
-
Risedronate Sodium: Reading the Repurposing Evidence
2026-10-03
Risedronate Sodium is best known as an FPP synthase inhibitor for osteoclast-mediated bone resorption inhibition, but preclinical work also examines its effects on alveolar macrophages. This evidence-focused analysis explains the pulmonary emphysema findings, the study’s methodological significance, and the boundaries between mechanistic promise and translational proof.
-
DAPI Nuclear Stain Solution Practical Guide
2026-10-02
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution, SKU K2402, provides a ready-to-use fluorescent DNA binding dye for nuclear visualization and endpoint cell viability assessment. It is best suited to fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, rather than routine imaging of intact live cells.
-
Alpha-Ketoglutarate at the Tumor–Immune Interface
2026-10-01
Alpha-ketoglutarate is emerging as more than a tricarboxylic acid cycle intermediate: it can connect tumor metabolic flux with macrophage immune function. This article translates recent cholangiocarcinoma findings into practical guidance for metabolic reprogramming research, enzyme system studies, and translational assay design.